OrganoClick AB
OrganoClick AB is a specialty chemicals company that develops and commercializes click chemistry reagents and building blocks for pharmaceutical and biotechnology applications.
Business. OrganoClick AB (ORGC.ST) is a specialty chemicals company headquartered in Sweden and listed on the Nasdaq Stockholm exchange. The firm operates within the Basic Materials sector, focusing on the development and production of chemical products. As specific operating segments and geographic breakdowns are not provided, the company is described at the industry level as a participant in the specialty chemicals market.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
OrganoClick AB (ORGC.ST) is a specialty chemicals company headquartered in Sweden and listed on the Nasdaq Stockholm exchange. The firm operates within the Basic Materials sector, focusing on the development and production of chemical products. As specific operating segments and geographic breakdowns are not provided, the company is described at the industry level as a participant in the specialty chemicals market.
OrganoClick's capital structure is highly leveraged, with a debt-to-equity ratio of 5.12, indicating significant reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.45 and negative free cash flow of -30.29 million SEK. The company's cash and equivalents of 2.68 million SEK are insufficient to cover its long-term debt of 77.78 million SEK, raising concerns about its ability to meet long-term obligations.
Profitability metrics are deeply negative, with a return on equity of -239.63% and a return on assets of -26.9%. These figures are well below the typical performance of the specialty chemicals industry, which generally expects positive returns on invested capital. The company reported a net loss of 36.37 million SEK and an operating loss of 31.57 million SEK, indicating a failure to generate sustainable earnings.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to sector-specific risks and limits the company's ability to offset losses in one area with gains in another.
Growth prospects are uncertain, with the company reporting a revenue of 106.19 million SEK in the latest period. Analysts have estimated a modest increase to 113.00 million SEK, but the company's operating and net losses suggest that any growth is not yet translating into profitability. The negative operating cash flow of -8.29 million SEK and free cash flow of -30.29 million SEK further indicate that the company is not generating sufficient cash to sustain operations or fund growth.
The company faces significant liquidity and dilution risks. The liquidity risk is rated as medium, with the company's net cash position being negative after subtracting total debt. The dilution risk is rated as low, but the company's negative earnings and cash flow may necessitate future equity raises, which could dilute existing shareholders.
Recent financial filings and transcripts indicate that the company is operating in a challenging market environment. The company's negative earnings and cash flow, combined with high debt levels, suggest that it is under pressure to improve its financial performance. No recent major events or strategic announcements have been disclosed that would indicate a clear path to profitability or growth.
- OrganoClick is highly leveraged with a debt-to-equity ratio of 5.12, indicating significant financial risk.
- The company reported a net loss of 36.37 million SEK and an operating loss of 31.57 million SEK, with no signs of profitability.
- Liquidity is weak, with a current ratio of 0.45 and negative free cash flow of -30.29 million SEK.
- Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
- Analysts expect modest revenue growth, but the company's negative cash flow and earnings suggest that any growth is not yet translating into profitability.
- The company's financial position raises concerns about its ability to meet long-term obligations and sustain operations.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,13 |
| Revenue | —no estimate | —no estimate | 113,0M SEK |
| Operating income | —no estimate | —no estimate | -8,0M SEK |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- OrganoClick AB Market data — financials · 2026-05-28
- OrganoClick AB Market data — analyst estimates · 2026-05-28